# Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

> **NCT01517399** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 28 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** tivantinib
- **DRUG:** omeprazole
- **DRUG:** s-warfarin
- **DRUG:** caffeine
- **DIETARY_SUPPLEMENT:** vitamin K
- **DRUG:** digoxin
- **DRUG:** midazolam

## Key facts

- **NCT ID:** NCT01517399
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-08
- **Final completion:** 2013-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517399, "Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01517399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*